Please enable JavaScript.
Coggle requires JavaScript to display documents.
Cancer Immunotherapy (Competitive Advantage (1.Immunological checkpoint…
Cancer Immunotherapy
Competitive Advantage
1.Immunological checkpoint therapy can effectively change the treatment outcome of patients with malignant cancer
2.Although the treatment can cause serious side effects, these side effects can be controlled
3.Can completely change the treatment of cancer, and it can also fundamentally change the treatment mode of future cancer
4.It has a very important breakthrough for cancer, and it has shown obvious therapeutic effects on different types of cancer patients in clinical trials.
5.It can specifically identify and kill cancer cells, and then re-infusion into the patient to achieve the purpose of treating tumors.
TIL and IL-2
Mainly for melanoma, kidney cancer, ovarian cancer
-
monoclonal antibodies
Cancer cell surface antigen variability is too large.For larger tumors, only the cells outside the cell can be killed
Allows the immune system to attack some normal organs, causing serious immune-related complications
cancer vaccines
Allows the immune system to attack some normal organs, causing serious immune-related complications
CAR-T
Targeting specific types of advanced, difficult to treat leukemia and lymphoma
-
-
Future
-
- The approach to predictive biomarkers for stratification will become more sophisticated
The industry is on the right path and on the cusp of some developments that have the ability to drastically change patient lives
With each new milestone comes a challenge, and the research and medical community will be focused on overcoming these challenges so we can make big strides in personalized medicine, and bring these major advancements to fruition.
- Combination drugs will become the next big thing.
Combination therapies have become of significant interest to the industry as they have shown great promise in clinical trials
Looking forward, the industry will look to move beyond this challenge and make advancements in combination therapies, seeking to make inroads particularly for melanoma as well as breast, lung, and prostate cancer.
- Quality of data will become just as important as the quantity.
The industry currently struggles with a lack of standardization around the way data is collected, shared, and analyzed, leading to data accuracy issues.
-
-
-
-
-
-
-
-
-
-